Company Overview
M. K. Proteins Limited engages in the manufactures and trades in vegetable refined oil and by-products in India. It offers rice bran, sunflower, cotton seed, soya bean, palm, canola, and rice bran bleached oils. The company also provides by-products, including rice bran fatty acid oils, rice bran waxes, gums, and spent earth; imports, processes, and sells crude oils; and trades in edible and non-edible oils. M. K. Proteins Limited was incorporated in 2012 and is based in Ambala, India.
Why Investors Should Care
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Mar 2026 Revenue of ₹382.88 Cr (+43.0% YoY); net profit ₹6.83 Cr.
- Trailing 12 Months Year-on-year growth — revenue +43.0%, earnings -18.7%.
- 5-Year Trend Long-term compounding — revenue CAGR 6.7%, profit CAGR -14.5%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 6.74% |
| 1 Year: | 43.02% |
Compounded Profit Growth
| 5 Years: | -14.52% |
| 1 Year: | -18.68% |
Stock Price Performance
| 1 Year: | -38.69% |
| 6 Months: | -23.73% |
| 3 Months: | -14.45% |
| 1 Month: | -9.46% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)32.95 · Neutral
P/E of 25.00 is above the sector median of 23.79 — pricier than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Generates positive free cash flow.
CONS
- Earnings shrank at -14.5% CAGR over 5 years.
- Trading 40.9% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Consumer Defensive).
| # | Name | CMP ₹ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | MKPL M. K. Proteins Limited NSE | 4.50 | 25.00 | ₹168.92 Cr | 0.00% | 14.29% | 8.95% | 6.74% | -14.52% |
| 2 | HINDUNILVR Hindustan Unilever Limited NIFTY50NSE | 2,115.10 | 33.05 | ₹4.97 L Cr | 2.05% | 22.15% | 30.86% | 2.31% | 14.12% |
| 3 | ITC ITC Limited NIFTY50NSE | 276.25 | 16.73 | ₹3.46 L Cr | 5.68% | 36.47% | 28.53% | 3.65% | 2.54% |
| 4 | NESTLEIND Nestlé India Limited NIFTY50NSE | 1,431.80 | 86.10 | ₹2.76 L Cr | 0.82% | 62.44% | 79.99% | 17.01% | 23.05% |
| 5 | DMART Avenue Supermarts Limited NSE | 3,911.80 | 85.73 | ₹2.55 L Cr | 0.00% | 16.41% | 12.14% | 17.21% | 7.69% |
| 6 | VBL Varun Beverages Limited NSE | 469.60 | 52.29 | ₹1.59 L Cr | 0.42% | 19.44% | 15.51% | 17.26% | 26.57% |
| 7 | BRITANNIA Britannia Industries Limited NSE | 5,325.50 | 50.63 | ₹1.28 L Cr | 1.69% | 61.27% | 49.61% | 5.66% | 2.95% |
| 8 | MARICO Marico Limited NIFTY_MIDNSE | 847.70 | 62.38 | ₹1.10 L Cr | 0.47% | 38.75% | 41.85% | 11.82% | 10.61% |
| 9 | GODREJCP Godrej Consumer Products Limited NSE | 1,060.60 | 58.31 | ₹1.09 L Cr | 1.84% | 21.44% | 14.71% | 4.59% | 3.02% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in INR.
| Metric | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Revenue | - | 137.20 Cr | 114.95 Cr | 32.43 Cr | 89.56 Cr | 145.94 Cr |
| Cost of Revenue | - | 131.72 Cr | 106.06 Cr | 30.85 Cr | 86.35 Cr | 142.33 Cr |
| Gross Profit | - | 5.48 Cr | 8.89 Cr | 1.58 Cr | 3.21 Cr | 3.61 Cr |
| Operating Expenses | - | 91.34 L | 3.48 Cr | 64.08 L | 96.52 L | 1.22 Cr |
| Operating Income | - | 4.57 Cr | 5.41 Cr | 94.00 L | 2.24 Cr | 2.39 Cr |
| EBITDA | - | 4.68 Cr | 5.51 Cr | 1.17 Cr | 2.38 Cr | 2.62 Cr |
| Interest Expense | - | 67.44 L | 70.16 L | 6.45 L | 29.56 L | 79.03 L |
| Pretax Income | - | 3.92 Cr | 4.71 Cr | 99.98 L | 1.97 Cr | 1.72 Cr |
| Tax Provision | - | 1.12 Cr | 1.19 Cr | 25.31 L | 53.55 L | 57.91 L |
| Net Income | - | 2.80 Cr | 3.51 Cr | 74.67 L | 1.43 Cr | 1.14 Cr |
| Diluted EPS | - | 0.07 | 0.09 | 0.02 | 0.04 | 0.03 |
Profit & Loss (Annual)
Figures in INR.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue | - | 314.86 Cr | 245.57 Cr | 267.71 Cr | 382.88 Cr |
| Cost of Revenue | - | 294.37 Cr | 223.92 Cr | 252.53 Cr | 368.43 Cr |
| Gross Profit | - | 20.49 Cr | 21.65 Cr | 15.18 Cr | 14.45 Cr |
| Operating Expenses | - | 3.69 Cr | 5.19 Cr | 3.10 Cr | 3.46 Cr |
| Operating Income | - | 16.81 Cr | 16.46 Cr | 12.08 Cr | 10.98 Cr |
| EBITDA | - | 17.65 Cr | 17.06 Cr | 12.91 Cr | 11.68 Cr |
| Interest Expense | - | 1.84 Cr | 1.07 Cr | 1.10 Cr | 1.85 Cr |
| Pretax Income | - | 14.99 Cr | 15.47 Cr | 11.45 Cr | 9.39 Cr |
| Tax Provision | - | 4.06 Cr | 4.26 Cr | 3.05 Cr | 2.56 Cr |
| Net Income | - | 10.93 Cr | 11.21 Cr | 8.40 Cr | 6.83 Cr |
| Diluted EPS | - | 0.29 | 0.30 | 0.22 | 0.18 |
Balance Sheet (Annual)
Figures in INR.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Total Assets | - | 103.22 Cr | 96.25 Cr | 130.57 Cr | 131.20 Cr |
| Current Assets | - | 98.58 Cr | 85.83 Cr | 118.52 Cr | 118.23 Cr |
| Cash & Equivalents | - | 6.25 L | 9.23 L | 3.38 L | 43.82 L |
| Inventory | - | 71.20 Cr | 79.27 Cr | 111.32 Cr | 109.78 Cr |
| Receivables | - | 16.06 Cr | 3.57 Cr | 1.40 Cr | 2.11 Cr |
| Total Liabilities | - | 53.36 Cr | 35.17 Cr | 61.10 Cr | 54.90 Cr |
| Current Liabilities | - | 49.63 Cr | 33.96 Cr | 59.00 Cr | 52.54 Cr |
| Long Term Debt | - | 2.54 Cr | 0 | 83.04 L | 1.05 Cr |
| Total Debt | - | 45.53 Cr | 20.08 Cr | 38.72 Cr | 37.14 Cr |
| Total Equity | - | 49.86 Cr | 61.08 Cr | 69.47 Cr | 76.30 Cr |
| Shares Outstanding | - | 37.54 Cr | 37.54 Cr | 37.54 Cr | 37.54 Cr |
Cash Flows (Annual)
Figures in INR.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -5.87 Cr | 32.42 Cr | -16.13 Cr | 5.43 Cr |
| Investing Cash Flow | - | 1.34 L | -5.88 Cr | -1.48 Cr | -1.60 Cr |
| Financing Cash Flow | - | 5.92 Cr | -26.51 Cr | 17.55 Cr | -3.43 Cr |
| Capital Expenditure | - | -72,052 | -5.90 Cr | -2.22 Cr | -1.90 Cr |
| Free Cash Flow | - | -5.88 Cr | 26.51 Cr | -18.35 Cr | 3.54 Cr |
| Net Change in Cash | - | 5.58 L | 2.98 L | -5.85 L | 40.44 L |
Ratios (Annual)
Figures in %.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Gross Margin % | - | 6.5% | 8.8% | 5.7% | 3.8% |
| Operating Margin % | - | 5.3% | 6.7% | 4.5% | 2.9% |
| Net Margin % | - | 3.5% | 4.6% | 3.1% | 1.8% |
| ROE % | - | 21.9% | 18.4% | 12.1% | 9.0% |
| ROCE % | - | 31.4% | 26.4% | 16.9% | 14.0% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for MKPL
Unpleasant Surprises Could Be In Store For M. K. Proteins Limited's (NSE:MKPL) Shares - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi4gFBVV95cUxNalhHbUQ1bjZ1VlEzSHlsWTlDaUREYkx0amhEcXhrUFFpNzRLc05DMGhUdEdjUHB5dzJqMXg4SWNmUkd6ZklCX3FWdG9wVEZER01jckhxQnMxVHJzVlpFVHF3Z21ZcngzSEVyc0NaNW9iS3VBUGNFOWw2UjVZRjBSMVVLSUdlVG5DN1B5eU…
M. K. Proteins Limited Schedules Board Meeting on May 29, 2026 to Consider Q4FY26 Audited Financial Results - scanx.trade
<a href="https://news.google.com/rss/articles/CBMi8wFBVV95cUxOT0pCYlhDNGNiWnRTX3cwWlNPSlFJYjNjWHJ3bV94UnJZOGpoOXBtSWVyVlBHQmlCQndBZFBXZkxrRDI3RFpUMGJIeUJuLWRxV2VOeXM2WjJmSzZtbjdla25EN2lIQVBZNXFQQktHUm5XSHpkSVdobVNvSGZfb3p3RGFFUV9tNS03TEN1Tk…
MKPL Stock Price and Chart — NSE:MKPL - TradingView
<a href="https://news.google.com/rss/articles/CBMiWEFVX3lxTE5HcXdMWnRQR25sREZXRTduRXhwT2hqdnY0QU1Cckp1bTdjNHVxSTNnR1NBUU5TQ2UxcEFFTVdvck0xUVZTTGJFNWNhc3FRYzRtbkh3dDc1Mkc?oc=5" target="_blank">MKPL Stock Price and Chart — NSE:MKPL</a> &…
M K Proteins Ltd. Share Price Today - M K Proteins Ltd. Stock Price Live NSE/BSE - CNBC TV18
<a href="https://news.google.com/rss/articles/CBMifEFVX3lxTE5EVy1pNGRkcVNlbTYyZnROc3I2anM5WjBHV0xNNXVkZmFtaktsR2g3RWF3SzAzeXJrdDhTSDNzVTBNWnhYeVZXTHREczVCZkgwMWpFV2pQNlRPY2hmTjJXbEplVi1FT1owdmlMb1RQTnZYSzFQZEY0akQ2cG4?oc=5" target="_blank">…
M K Proteins Share Price - Upstox
<a href="https://news.google.com/rss/articles/CBMia0FVX3lxTE1UZTFrRnBjcUxDdEotTWJCOElxbmNtV1QwMU90ZF9uVTZIUmFSbE44WF9GUVVHZ2lJU3pWWVZuOWVwUUhGS3hTVExoUmloYk5SeWp1N09vMl9MUVVhLVI5REhERFZjWktTU1BN?oc=5" target="_blank">M K Proteins Share Pric…
Citi Pharma partners with Indian firm - Dawn
<a href="https://news.google.com/rss/articles/CBMiSEFVX3lxTE95YUlja1BGWXdfRU9JaEp3UjhWN245OUh3UWpTOE5NdFpPUFZRZUx5ZWRpNkpYTG1qY2RTU2R2YUwwQnhLX3VzSdIBTkFVX3lxTE14LTY0MFh5T25UQi10Yk5BMEVkSlVFc2Ywc1JDV2JJcnhEN2pFaEhzdTJ5cjF1bk5sci1mYk5yd1BoRX…
MKPL — Frequently Asked Questions
What is the current share price of M. K. Proteins Limited (MKPL)?
As of 2026-07-15 09:52 IST, M. K. Proteins Limited (MKPL) trades at ₹4.50 on NSE. Its 52-week range is ₹3.87 to ₹7.61.
What is the market capitalisation of MKPL?
M. K. Proteins Limited (MKPL) has a market capitalisation of ₹168.92 Cr on NSE.
What is the P/E ratio of MKPL?
MKPL trades at a trailing price-to-earnings (P/E) ratio of 25.00. The industry average P/E is 23.79. Its price-to-book (P/B) ratio is 2.29.
What is the return on equity (ROE) of MKPL?
MKPL has a return on equity (ROE) of 8.95%. Its return on capital employed (ROCE) is 14.29%.
Is MKPL a good stock to buy?
This page provides a data-driven analysis of M. K. Proteins Limited (MKPL), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.